Metastases To The Choroid
AURAAura Biosciences IncCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Belzupacap Sarotalocan (AU-011) (Virus-Like Conjugate) in Metastases To The Choroid. The expected timing is based on the latest available company guidance and may change.
11/13/25:- First patient dosed in the ongoing Ph2 bel-sar trial for metastases to the choroid, entry criteria expanded to include metastases from multiple solid tumors, and early four-week proof-of-concept efficacy data expected in 2026. 03/30/26:- Ph2 choroidal metastases trial continues enrolling; early proof-of-concept data remains expected in 2026. 05/11/26:- Ph2 choroidal metastases trial enrolling; early four-week efficacy data still expected in 2026. 08/11/26:- Ph2 choroidal metastases program advancing; Q1 2027 update expected.
Verification
Confirm timing and program details against the company announcement or filing.